Patents by Inventor Kathryn Armour

Kathryn Armour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides including modified constant regions
    Publication number: 20070041966
    Abstract: Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having increased binding affinity for an Fc?R, which processes comprise modifying the polypeptides by substitution of the amino acid at position 268 of a human IgG CH2 region for a non-native polar or charged amino acid e.g. Gin, Asn, Glu, or Asp. also provided are corresponding polypeptides, nucleic acids, and methods of use of the same e.g. in improved lytic therapies.
    Type: Application
    Filed: October 27, 2006
    Publication date: February 22, 2007
    Applicant: XENCOR, INC.
    Inventors: Kathryn Armour, Michael Clark
  • Polypeptides including modified constant regions
    Publication number: 20050215768
    Abstract: Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having increased binding affinity for an Fc?R, which processes comprise modifying the polypeptides by substitution of the amino acid at position 268 of a human IgG CH2 region for a non-native polar or charged amino acid e.g. Gln, Asn, Glu, or Asp. also provided are corresponding polypeptides, nucleic acids, and methods of use of the same e.g. in improved lytic therapies.
    Type: Application
    Filed: October 7, 2004
    Publication date: September 29, 2005
    Inventors: Kathryn Armour, Michael Clark
  • CDR grafted type III anti-CEA humanized mouse monoclonal antibodies
    Publication number: 20050089538
    Abstract: A Class III, anti-CEA monoclonal antibody, preferably a monoclonal antibody comprising the complementarity-determining regions (CDRs) of a parental murine Class III, anti-CEA monoclonal antibody is disclosed. This monoclonal antibody is preferably a humanized monoclonal antibody in which the CDRs are engrafted to the framework regions of a heterologous antibody, wherein the humanized monoclonal antibody retains the binding specificity of the parental murine monoclonal antibody. A preferred Class III, anti-CEA monoclonal antibody is one in which the preferred heterologous antibody is from a human. Also provided are DNA constructs, vectors, cells and methods for producing the Class III, anti-CEA monoclonal antibodies, and diagnostic and therapeutic conjugates using same. Methods of treatment with a Class III, anti-CEA monoclonal antibody and with the conjugate containing this monoclonal antibody are provided as well as methods of diagnosis with the conjugate containing this monoclonal antibody.
    Type: Application
    Filed: January 13, 2004
    Publication date: April 28, 2005
    Inventors: Hans Hansen, Kathryn Armour
  • High affinity humanized anti-tag-72 monoclonalantibodies
    Patent number: 6753152
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: June 22, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-Tag-72 monoclonal antibodies
    Patent number: 6753420
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: June 22, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonal antibodies
    Patent number: 6752990
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: June 22, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonal antibodies
    Patent number: 6737061
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: May 18, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonal antibodies
    Patent number: 6737060
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: May 18, 2004
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20030027994
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: February 6, 2003
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20030018171
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: January 23, 2003
    Inventors: W.H Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Publication number: 20030013854
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: January 16, 2003
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Publication number: 20030013856
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: January 16, 2003
    Inventors: W.H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-tag-72 monoclonalantibodies
    Publication number: 20030004318
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: January 2, 2003
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-tag-72 monoclonalantibodies
    Publication number: 20020193574
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: December 19, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20020183495
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: December 5, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Publication number: 20020183497
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Application
    Filed: October 31, 2001
    Publication date: December 5, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Publication number: 20020165387
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: October 9, 2001
    Publication date: November 7, 2002
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • High affinity humanized anti-CEA monoclonal antibodies
    Patent number: 6417337
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Grant
    Filed: February 18, 1998
    Date of Patent: July 9, 2002
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
  • HIGH AFFINITY HUMANIZED ANIT-CEA MONOCLONAL ANTIBODIES
    Publication number: 20020052479
    Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
    Type: Application
    Filed: February 18, 1998
    Publication date: May 2, 2002
    Inventors: KERR W.H. ANDERSON, PHILIP TEMPEST, FRANK J CARR, WILLIAM J HARRIS, KATHRYN ARMOUR
  • High affinity humanized anti-TAG-72 monoclonalantibodies
    Patent number: 6348581
    Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.
    Type: Grant
    Filed: February 18, 1998
    Date of Patent: February 19, 2002
    Assignee: The Dow Chemical Company
    Inventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour